The increasing incidences of lifestyle based diseases due to excessive drinking and smoking habits coupled with rising incidences of chronic diseases such as kidney tumors and kidney cancer has led to growth in the kidney cancer drugs market. The increasing geriatric population base globally is also the factor expected to further boost the growth of this market as they are more prone to chronic diseases. Additionally, the patients as well as clinicians prefer kidney cancer drugs over the targeted therapies. For the advanced stage metastatic tumor patients, cancer drugs are life saving and prolonging treatment regimens.
To request a sample copy or view summary of this report, click the link below:
Nexavar is expected to have the largest share in the market owing to its common usage in several diseases during the forecast period. The different brands used as kidney cancer drugs are Inlyta (Axitnib), Nexavar (Sorafebin), Afinitor (Everolimus), Avastin (Bevaciazumab), Votrient (Pazopanib), Torisel (temosirolimus), Sutent and Proleukin (Interlukin-2/ Aldesleukin). It also combines the pipeline analysis for various potential drugs which are currently in phase II and phase III trials.. On the basis of region, the North America dominates the kidney cancer drugs market. The largest share of this region is due to the rising incidences of cancer and other kidney diseases. However, Asia Pacific is expected to witness a huge rise in the market share due to the low costs of drug production and increasing renal cell carcinoma patient base in this region.
To request a sample copy or view TOC of this report, click the link below:
Various companies are creating their marketing strategies such as collaborations, expansions and new innovations to maintain their market share in the kidney cancer drugs...